PDCD1 and glioblastoma: Even though this evidence shows remodeling and increased levels of intratumoral T cells, it would be therapeutically relevant to determine whether supportive measures to replenish and revitalize the lymphoid compartment would improve clinical outcomes in lymphopenic GBM patients treated with neoadjuvant PD-1 blockade or other immunotherapies.